Proprietary Pipeline
Undisclosed intractable diseases (e.g., cancers, immune disorders)
Discovery/PreclinicalActive
Key Facts
Indication
Undisclosed intractable diseases (e.g., cancers, immune disorders)
Phase
Discovery/Preclinical
Status
Active
Company
About BigHat Biosciences
BigHat Biosciences is a private, Series B biotech company leveraging a proprietary integrated platform called Milliner to revolutionize antibody discovery and engineering. The platform synergizes high-throughput synthetic biology labs with advanced machine learning models to design, build, and test hundreds of antibody variants weekly, significantly compressing development timelines. The company has a pipeline of over ten therapeutic programs, engages in strategic partnerships with major pharma, and has raised over $100 million from top-tier investors to advance its mission of creating better biologics faster.
View full company profile